Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus-related Lymphomas
| Autor: | José-Tomás Navarro, Josep Muncunill, Miriam Moreno, Maria Joao Baptista, Agueda Hernandez-Rodriguez, Judith Dalmau, Josep-Maria Ribera, Gustavo Tapia, Juan-Manuel Sancho, Evarist Feliu, Olga García, José-Luis Mate, Javier Martinez-Picado |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Oncology Adult Male medicine.medical_specialty Prognostic factor Herpesvirus 4 Human 030106 microbiology Human immunodeficiency virus (HIV) HIV Infections medicine.disease_cause Virus law.invention 03 medical and health sciences Young Adult 0302 clinical medicine immune system diseases law Risk Factors hemic and lymphatic diseases Internal medicine medicine Humans 030212 general & internal medicine Polymerase chain reaction Aged Lymphoma AIDS-Related Aged 80 and over business.industry Area under the curve Middle Aged Viral Load medicine.disease Epstein–Barr virus Lymphoma Infectious Diseases Case-Control Studies Biomarker (medicine) Female business Biomarkers |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 68(5) |
| ISSN: | 1537-6591 |
| Popis: | Epstein-Barr virus (EBV) has been implicated in lymphomagenesis and can be found infecting tumor cells and in plasma at lymphoma diagnosis, especially in human immunodeficiency virus (HIV)-infected patients. Our aim was to evaluate the usefulness of plasma EBV load as biomarker and prognostic factor in HIV-positive patients with lymphomas.EBV loads were measured by polymerase chain reaction in plasma samples of 81 HIV-positive patients' lymphomas at different moments: within 1 year before lymphoma diagnosis, at diagnosis, and at complete response (CR). Control samples included HIV-negative patients with lymphomas and HIV-positive patients without neoplasia or opportunistic infections.HIV-positive patients with lymphomas had more frequently-detectable EBV load at lymphoma diagnosis (53%) than either HIV-negative patients with the same lymphoma type (16%; P.001) or HIV-positive individuals without neoplasia or opportunistic infection (1.2%; P.001). HIV-positive lymphoma patients with detectable EBV load in plasma at lymphoma diagnosis had statistically significant decrease of EBV load at CR. High EBV load (5000 copies/mL) at lymphoma diagnosis was an independent negative prognostic factor for overall survival and progression-free survival in HIV-positive patients with lymphomas. Detectable plasma EBV loads identified HIV-positive subjects that would eventually develop lymphoma (area under the curve, 82%; 95% CI: 0.67-0.96).Plasma EBV load can be used as a biomarker and as a prognostic factor in HIV-positive patients with lymphomas. The presence of the EBV load in the plasma of an HIV-positive patient can be an early predictor of lymphoma development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|